RxDoctor Payments Data

Katie Neese

Adult Health · Fairhope, ALNPI 1891175428

Payments from drug & device makers

$1,329in general payments, 2019–2025

Across 29 payments — averaging $45.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$578
  • AstraZeneca$245
  • Alnylam Pharmaceuticals Inc.$120
  • Nxstage Medical, Inc.$85
  • Aurinia Pharma U.S., Inc.$73
  • Mallinckrodt Hospital Products Inc.$65
  • plus $162 from 6 others

What the payments were for

  • Food & beverage$1,329100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,329 in reported general payments places this provider in the 65th percentile of 308 adult health providers in Alabama.

See all adult health providers in Alabama

Medicare billing

Part B allowed, 2024
$16,300
Medicare patients
72
Services billed
160

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide52$128,425
AuryxiaFerric Citrate36$99,120
OzempicSemaglutide12$11,689
Sevelamer Carbonate37$5,035
Lidocaine-PrilocaineLidocaine/Prilocaine50$1,074
Ropinirole Hcl18$256
Ondansetron Hcl16$247
Amlodipine Besylate29$183
Hydralazine Hcl13$179
Trazodone Hcl20$146
Losartan Potassium19$141
Promethazine Hcl11$140
Atorvastatin Calcium17$118
Carvedilol25$114
Furosemide25$104

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Akebia Therapeutics IncAuryxia$18$99,12036 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 308 adult health providers in Alabama.

Other adult health in Fairhope

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →